Pharmacogenetic interactions of medications administered for weight loss in adults: a systematic review and meta-analysis.

IF 1.9 4区医学 Q3 PHARMACOLOGY & PHARMACY Pharmacogenomics Pub Date : 2023-04-01 Epub Date: 2023-03-31 DOI:10.2217/pgs-2022-0192

Joelle BouSaba, Kia Vosoughi, Saam Dilmaghani, Larry J Prokop, Michael Camilleri

{"title":"Pharmacogenetic interactions of medications administered for weight loss in adults: a systematic review and meta-analysis.","authors":"Joelle BouSaba, Kia Vosoughi, Saam Dilmaghani, Larry J Prokop, Michael Camilleri","doi":"10.2217/pgs-2022-0192","DOIUrl":null,"url":null,"abstract":"Aim: To analyze roles of single nucleotide variants (SNVs) on weight loss with US FDA-approved medications. Materials & methods: We searched the literature up until November 2022. Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines were followed. Results: 14 studies were included in qualitative analysis and seven in meta-analysis. SNVs in CNR1, GLP-1R, MC4R, TCF7L2, CTRB1/2, ADIPOQ, SORCS1 and ANKK1 were evaluated relative to weight loss with glucagon-like peptide-1 agonists (13 studies) or naltrexone-bupropion (one study). CNR1 gene (rs1049353), GLP-1R gene (rs6923761, rs10305420), TCF7L2 gene (rs7903146) were associated with weight loss in at least one study involving glucagon-like peptide-1 agonist(s). The meta-analysis did not identify any consistent effect of SNVs. Conclusion: Pharmacogenetic interactions for exenatide, liraglutide, naltrexone-bupropion and weight loss were identified, but the directionality was inconsistent.","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152409/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pgs-2022-0192","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/3/31 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To analyze roles of single nucleotide variants (SNVs) on weight loss with US FDA-approved medications. Materials & methods: We searched the literature up until November 2022. Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines were followed. Results: 14 studies were included in qualitative analysis and seven in meta-analysis. SNVs in CNR1, GLP-1R, MC4R, TCF7L2, CTRB1/2, ADIPOQ, SORCS1 and ANKK1 were evaluated relative to weight loss with glucagon-like peptide-1 agonists (13 studies) or naltrexone-bupropion (one study). CNR1 gene (rs1049353), GLP-1R gene (rs6923761, rs10305420), TCF7L2 gene (rs7903146) were associated with weight loss in at least one study involving glucagon-like peptide-1 agonist(s). The meta-analysis did not identify any consistent effect of SNVs. Conclusion: Pharmacogenetic interactions for exenatide, liraglutide, naltrexone-bupropion and weight loss were identified, but the directionality was inconsistent.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

成人减肥用药的药物遗传学相互作用：系统回顾和荟萃分析。

目的：分析单核苷酸变异（SNV）对美国 FDA 批准的减肥药物的作用。材料与方法：我们检索了截至 2022 年 11 月的文献。我们遵循了《系统综述和元分析首选报告项目》（Preferred Reporting Items for Systematic Review and Meta-Analyses）指南。结果14项研究被纳入定性分析，7项研究被纳入荟萃分析。评估了 CNR1、GLP-1R、MC4R、TCF7L2、CTRB1/2、ADIPOQ、SORCS1 和 ANKK1 中的 SNV 与胰高血糖素样肽-1 激动剂（13 项研究）或纳曲酮-安非他酮（1 项研究）治疗体重减轻的关系。在至少一项涉及胰高血糖素样肽-1 激动剂的研究中，CNR1 基因（rs1049353）、GLP-1R 基因（rs6923761、rs10305420）、TCF7L2 基因（rs7903146）与体重减轻有关。荟萃分析未发现 SNV 有任何一致的影响。结论发现了艾塞那肽、利拉鲁肽、纳曲酮-安非他酮与体重减轻的药物遗传学相互作用，但其方向性并不一致。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Pharmacogenomics 医学-药学

CiteScore

3.40

自引率

9.50%

发文量

审稿时长

4-8 weeks

期刊介绍： Pharmacogenomics (ISSN 1462-2416) is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field. Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.